Search

Objective: To study clinical research of ulinastatin in treatment of bronchial asthma and analysis of the changes of serum interleukin (IL)-2, IL-4 and T cell subsets. Methods: 98 patients of bronchial asthma who received therapy from January 2014 to October 2016 in our hospital were selected. According to random number table, those patients were divided into the observation group (n=49) and the control group (n=49). The control group was treated with routine treatment, including anti inflammation, improve ventilation, correct acid-base balance disorders, inhaled corticosteroids and β2 receptor agonists, electrolytes, etc, while the observation group was combined with ulinastatin treatment. The clinical efficacy and clinical symptom regression time were compared, and collection 3ml fasting venous blood was collected before and after treatment, the changes of serum IL-2, IL-4 and T cell subsets were detected by flow cytometry. Results: After treatment, the total effective rate in the observation group was significantly higher than that of the control group (P＜0.05); the dyspnea, wheeze, chest tightness, cough symptoms subsided time in the observation group was significantly shorter than that of the control group (P ＜0.05); before treatment, there was no significant difference in serum IL-2 and IL-4 between the two groups(P＞0.05), compared with before treatment, the serum IL-2 and IL-4 were significantly improved in the two groups after treatment (P ＜0.05), the serum IL-2 in the observation group was significantly higher than that of the control group, the serum IL-4 was significantly lower than that of the control group (P＜0.05); There was no significant difference in CD3+, CD4+, CD8+ and CD4+/CD8+ between the two groups (P＞0.05), compared with before treatment, the CD3+, CD4+, CD8+ and CD4+/CD8+were significantly improved in the two groups after treatment (P＜0.05), the CD3+, CD4+ and CD4+/CD8+ in the observation group were significantly higher than those of the control group, and the CD8+was significantly lower than that of the control group (P＜0.05). Conclusion: Ulinastatin is well for bronchial asthma, which can effectively relieve clinical symptoms, to improve the expression of serum IL-2, IL-4 and T cell subsets, regulation of immune function, high clinical value. [ABSTRACT FROM AUTHOR]